Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Rating of “Moderate Buy” from Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has been given a consensus recommendation of “Moderate Buy” by the twenty-four brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, eleven have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $86.2632.

Several research analysts have weighed in on EW shares. Stifel Nicolaus boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a report on Friday, July 25th. Mizuho boosted their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Barclays boosted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Finally, Robert W. Baird boosted their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, July 25th.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the business. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $28,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences during the 4th quarter worth $27,000. Quantbot Technologies LP acquired a new position in Edwards Lifesciences in the 1st quarter worth $26,000. NewSquare Capital LLC lifted its holdings in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Finally, SouthState Corp acquired a new position in Edwards Lifesciences in the 1st quarter worth $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 1.9%

Shares of Edwards Lifesciences stock opened at $76.10 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a market capitalization of $44.68 billion, a P/E ratio of 10.95, a P/E/G ratio of 3.74 and a beta of 1.07. The business has a 50 day moving average price of $78.91 and a 200 day moving average price of $75.48.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm posted $0.70 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.